Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A condition characterized by the abnormal presence of monoclonal immunoglobulins in the blood or urine.
Biomarker and diagnostic research for monoclonal gammopathy has been reported in the published literature.
43 clinical trials registered, 22 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 10 PHASE2, 1 PHASE1, 9 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07209371](https://clinicaltrials.gov/study/NCT07209371) |
Data assembled from 3 of 12 sources · Last updated Nov 4, 2026, 2:38 AM UTC
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance |
PHASE2 |
Fred Hutchinson Cancer Center |
RECRUITING |
[NCT06065852](https://clinicaltrials.gov/study/NCT06065852) | National Registry of Rare Kidney Diseases | — | UK Kidney Association | RECRUITING |
[NCT06383143](https://clinicaltrials.gov/study/NCT06383143) | Promoting Diagnosis and Management of AL in Italy (ProDigALIty) | — | Fondazione IRCCS Policlinico San Matteo di Pavia | RECRUITING |
[NCT02269592](https://clinicaltrials.gov/study/NCT02269592) | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | — | Dana-Farber Cancer Institute | RECRUITING |
[NCT06559033](https://clinicaltrials.gov/study/NCT06559033) | Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS | — | University Hospital, Rouen | RECRUITING |
202 publications have been identified in PubMed for monoclonal gammopathy. Research spans Review / Meta-Analysis (31%), Case Report / Case Series (20%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 58 | 31% |
Patient case studies | 37 | 20% |
Laboratory research | 31 | 17% |
Disease patterns and progression | 26 | 14% |
Testing and diagnosis research | 13 | 7% |
Clinical study results | 13 | 7% |
Other research | 8 | 4% |
New treatment approaches | 1 | 1% |
Mir TH (2026). [PMID: 41740896](https://pubmed.ncbi.nlm.nih.gov/41740896/). *J Am Acad Dermatol*. [Other]
Li XY (2026). [PMID: 41935257](https://pubmed.ncbi.nlm.nih.gov/41935257/). *BMC Nephrol*. [Case Report / Case Series]
Kanack AJ (2026). [PMID: 41841750](https://pubmed.ncbi.nlm.nih.gov/41841750/). *Br J Haematol*. [Review / Meta-Analysis]
Khalighi MA (2026). [PMID: 41949853](https://pubmed.ncbi.nlm.nih.gov/41949853/). *JAMA Dermatol*. [Epidemiology / Natural History]
Zhang C (2026). [PMID: 41526545](https://pubmed.ncbi.nlm.nih.gov/41526545/). *Clin Exp Med*. [Epidemiology / Natural History]
Cantley MD (2026). [PMID: 41565487](https://pubmed.ncbi.nlm.nih.gov/41565487/). *Pathology*. [Review / Meta-Analysis]
Fu Y (2026). [PMID: 41609080](https://pubmed.ncbi.nlm.nih.gov/41609080/). *Front Biosci (Landmark Ed)*. [Basic Science / Preclinical]
Bu L (2026). [PMID: 41883004](https://pubmed.ncbi.nlm.nih.gov/41883004/). *Curr Opin Nephrol Hypertens*. [Review / Meta-Analysis]
Manne SC (2026). [PMID: 42085062](https://pubmed.ncbi.nlm.nih.gov/42085062/). *Niger Postgrad Med J*. [Case Report / Case Series]
Surapaneni M (2026). [PMID: 41656113](https://pubmed.ncbi.nlm.nih.gov/41656113/). *Blood Rev*. [Review / Meta-Analysis]
AI-curated news mentioning monoclonal gammopathy
Updated Oct 11, 2026
A study analyzed 15,068 cases in China using mass spectrometry to screen for monoclonal gammopathy during routine physical exams. This research could enhance early detection strategies for this condition.
A new guide for nephrologists on monoclonal gammopathy of clinical significance has been published, providing insights into diagnosis and management. This resource aims to enhance understanding of the condition and its implications for kidney health.
A rare case report details concurrent light chain proximal tubulopathy and crystal-storing histiocytosis in a patient with monoclonal gammopathy of renal significance, highlighting the complexities of these conditions over a 4-year follow-up. This study contributes to the understanding of rare renal pathologies associated with monoclonal gammopathy.